Perrigo Q4 2024 Earnings Report
Key Takeaways
Perrigo's Q4 2024 revenue declined by 1.6% year-over-year to $1.14 billion due to divested businesses and currency impact, while adjusted EPS increased to $0.93 from $0.86 in the prior year. Adjusted operating income grew by 16% to $194 million, benefiting from cost-saving initiatives. The company's net loss widened to $41 million due to restructuring and litigation-related charges, but strong performance in infant formula sales helped offset declines in other categories.
Net sales decreased 1.6% year-over-year to $1.14 billion.
Adjusted EPS increased by 8.1% to $0.93.
Adjusted operating income grew 16% to $194 million, driven by efficiency improvements.
Net loss widened to $41 million due to restructuring and litigation expenses.
Perrigo Revenue
Perrigo EPS
Perrigo Revenue by Segment
Forward Guidance
Perrigo expects continued growth in core product categories and benefits from cost-saving initiatives in 2025.
Positive Outlook
- Revenue growth projected in the mid-single digits for fiscal 2025.
- Continued market share gains in infant formula and women's health categories.
- Operational efficiency improvements expected to drive margin expansion.
- Strategic investments in innovation and e-commerce expected to support growth.
- Improved cash flow generation anticipated with further debt reduction.
Challenges Ahead
- Potential headwinds from currency fluctuations affecting international sales.
- Ongoing litigation expenses may impact profitability.
- Rising raw material and supply chain costs could pressure margins.
- Competitive pressures in key product categories may affect pricing power.
- Macroeconomic uncertainty could influence consumer spending trends.
Revenue & Expenses
Visualization of income flow from segment revenue to net income